Abstract 4361892: CKD and CKM Syndrome: Accelerated Progression to Arrhythmias in a National Cohort

P Pierantonio Russo (EVERSANA LLC, Cherry Hill, New Jersey, United States) R Ramaa Nathan (EVERSANA LLC, Cherry Hill, New Jersey, United States) J Jason Poh (EVERSANA LLC, Cherry Hill, New Jersey, United States) H Harjeet Singh (Division of Pediatrics, Department of Pediatrics–Research, The University of Texas MD Anderson Cancer Center) K Ken Boyle (irhythm, San Francisco, California, United States) B Brent Wright (iRhythm Tech, Washougal, Washington, United States) E Erik Hendrickson (iRhythm Tech, Washougal, Washington, United States)

Abstract

Introduction: Chronic kidney disease (CKD), a key element of the AHA Cardiovascular-Kidney-Metabolic (CKM) framework, is increasingly recognized as an independent risk factor for arrhythmias, especially atrial fibrillation (AF). Studies like ARIC and recent guidelines highlight higher arrhythmia risk with declining kidney function, but real-world data (RWD) on this progression are limited. This study examines arrhythmia onset in patients progressing from obesity to CKD. Methods: We conducted a retrospective real-world evidence study using the Symphony Integrated Dataverse (2018–2024) to examine arrhythmia development in adults with obesity initially classified as CKM Stage 1—defined by the absence of metabolic or cardiac risk factors at the time of obesity diagnosis (Fig. 1). A subset who progressed to CKD (Stages 1–4) but remained free of cardiac risk factors at CKD onset, were followed longitudinally to evaluate the incidence of major arrhythmias. All patients had a minimum of 12 months of baseline (lookback) data and 12 months of follow-up after their initial obesity diagnosis. Results: The cohort included 3.5 million adults with obesity (33% male, 67% female; median age 37 years) (Fig. 2). Of these, 26,478 patients (41% male, 59% female; median age 60 years) progressed to CKD: Stage 1 (7%), Stage 2 (32%), Stage 3 (57%), and Stage 4 (3%). After CKD onset, 1,095 patients (4%) (54% male, 46% female; median age 70 years) developed a major arrhythmia—65% atrial fibrillation (AF), 14% supraventricular tachycardia, 16% atrioventricular block, and 3% ventricular tachycardia—within a median of 4 months (Fig. 3). Between obesity diagnosis and CKD development, 27% developed hypertension, 12% diabetes, and 7% both (Fig. 4). Notably, 70% of all arrhythmia cases occurred in patients with CKD Stage 3. Conclusion: In this real-world cohort, progression from cardiometabolic dysfunction to CKD was associated with a marked rise in new arrhythmias, particularly AF. Early-onset obesity patients who developed CKD had a markedly higher progression to arrhythmia or MACE before age 40. These findings support CKD as a key inflection point in arrhythmia risk and reinforce the CKM framework. Enhanced surveillance for arrhythmias may be warranted as kidney function declines.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (7)

P

Pierantonio Russo

EVERSANA LLC, Cherry Hill, New Jersey, United States

R

Ramaa Nathan

EVERSANA LLC, Cherry Hill, New Jersey, United States

J

Jason Poh

EVERSANA LLC, Cherry Hill, New Jersey, United States

H

Harjeet Singh

Division of Pediatrics, Department of Pediatrics–Research, The University of Texas MD Anderson Cancer Center

K

Ken Boyle

irhythm, San Francisco, California, United States

B

Brent Wright

iRhythm Tech, Washougal, Washington, United States

E

Erik Hendrickson

iRhythm Tech, Washougal, Washington, United States